The stock of Sangamo Therapeutics Inc (NASDAQ: SGMO) has decreased by -1.04 when compared to last closing price of 0.50. Despite this, the company has experienced a -3.98% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-12 that Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie – Vice President, Investor Relations and Corporate Communications Sandy Macrae – Chief Executive Officer Nathalie Dubois-Stringfellow – Chief Development Officer Prathyusha Duraibabu – Chief Financial Officer Conference Call Participants Nicole Germino – Truist Luis Santos – H.C. Wainwright Operator Good afternoon and welcome to the Sangamo Therapeutics First Quarter 2025 Teleconference Call.
Is It Worth Investing in Sangamo Therapeutics Inc (NASDAQ: SGMO) Right Now?
The 36-month beta value for SGMO is at 1.21. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for SGMO is 237.58M, and currently, shorts hold a 13.05% of that float. The average trading volume for SGMO on June 17, 2025 was 6.96M shares.
SGMO’s Market Performance
SGMO’s stock has seen a -3.98% decrease for the week, with a 5.28% rise in the past month and a -41.52% fall in the past quarter. The volatility ratio for the week is 2.39%, and the volatility levels for the past 30 days are at 3.28% for Sangamo Therapeutics Inc The simple moving average for the last 20 days is 0.83% for SGMO stock, with a simple moving average of -57.32% for the last 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with Truist repeating the rating for SGMO by listing it as a “Buy.” The predicted price for SGMO in the upcoming period, according to Truist is $7 based on the research report published on December 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $10. The rating they have provided for SGMO stocks is “Buy” according to the report published on December 10th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to SGMO, setting the target price at $2 in the report published on November 03rd of the previous year.
SGMO Trading at -18.10% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.44% of loss for the given period.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -1.29 for the present operating margin
- 0.96 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -1.25. The total capital return value is set at -2.24. Equity return is now at value -262.12, with -75.06 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at -1.79.
Currently, EBITDA for the company is -89.09 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 1.91. The receivables turnover for the company is 13.83for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.76.
Conclusion
In conclusion, Sangamo Therapeutics Inc (SGMO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
